Article

VIDEO: Ketamine, Glutamate, and the Future of Mood Disorders Therapeutics

user
November 28
Recommended by Mani Pavuluri
article

                                                                     WATCH HERE

In this webinar, Dr. Sanjay Mathew will review the history of ketamine for the treatment of serious depressive disorders and other similar treatments in development.  Ketamine is an anesthetic drug which has recently been re-purposed at low doses for the treatment of severe mood disorders, PTSD, and suicidal ideation. The mechanism of its activity in the brain involves changes in the activity of glutamate, which is the primary amino acid neurotransmitter in the brain. Glutamate is critical for fundamental brain activities such as learning and mood. This webinar will review the history of ketamine for the treatment of serious depressive disorders. Additional drugs in development which impact glutamate and one of its primary receptors (NMDA) will also be discussed.   Sanjay J. Mathew, M.D. is the Johnson Family Chair for Research in Psychiatry, Professor with Tenure in the Menninger Department of Psychiatry & Behavioral Sciences, and director of the Mood and Anxiety Disorders Research Program at Baylor College of Medicine.  He is also a staff psychiatrist at the Michael E. Debakey VA Medical Center in Houston, Texas.  He completed his psychiatric residency at Columbia University and the New York State Psychiatric Institute, where he also completed a NIMH-funded research fellowship in affective and anxiety disorders.   Dr. Mathew began his faculty career at the Mount Sinai School of Medicine, where he co-founded and directed the Mood and Anxiety Disorders Program.   His research program funded by NIMH, Department of Veterans Affairs, and industry, focuses on experimental therapeutics and pathophysiology of treatment-resistant depression and trauma and stress-related disorders. Dr. Mathew has published approximately 100 articles in leading scientific journals, and serves on the editorial board of several journals.  He is an elected member of the American College of Neuropsychopharmacology and has been selected in Best Doctors every year since 2011.   He is co-editor of the book, Ketamine for Treatment-Resistant Depression: The First Decade of Progress, published in 2016.  

International Bipolar Foundation is not intended to be a substitute for professional medical advice, diagnosis or treatment. We do not recommend any specific treatment, drug, food or supplement. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional advice because of something you have read from IBPF. 

Comments

Only healthcare providers are able to comment

If you are a healthcare provider, claim your profile now

Claim